Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **ocular surface cell membrane** refers to the plasma membrane of epithelial cells at the front of the eye, including those of the cornea and conjunctiva[2][3]. It forms the substrate for specialized glycocalyx components, especially membrane-associated mucins, which serve essential roles in hydration, tear film stability, lubrication, and barrier protection[1][4]. This membrane is highly specialized, featuring microplicae and microvilli that increase surface area and capacity to bind water via glycoproteins[3]. Disease states such as dry eye and ocular surface disorders are associated with alterations in the mucin coat and glycocalyx structure, compromising barrier function and tear stability[1][4]. However, the plasma membrane itself is not an accepted molecular target for therapeutic intervention; rather, membrane-associated proteins (e.g., mucins MUC1, MUC4, MUC16) are the actionable targets in ocular surface biology[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ocular Surface Cell Membrane.